Anal Human Papillomavirus Prevalence Among Vaccinated and Unvaccinated Gay, Bisexual, and Other Men Who Have Sex With Men in Canada
Authors:
- Catharine ChambersCCCatharine Chambers
- Shelley L. DeeksSDShelley L. Deeks
- Rinku SutradharRSRinku Sutradhar
- Joseph CoxJCJoseph Cox
- Alexandra de PokomandyAPAlexandra de Pokomandy
- Troy GrennanTGTroy Grennan
- Trevor A. HartTHTrevor A. Hart
- Gilles LambertGLGilles Lambert
- David M. MooreDMDavid M. Moore
- François CoutléeFCFrançois Coutlée
- Ann N. BurchellABAnn N. Burchell
- the Engage-HPV Study TeamTTthe Engage-HPV Study Team
Open Access
- 22 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 49 (2) , 123-132
Abstract
Background: Starting in 2015, human papillomavirus (HPV) vaccine has been publicly funded for gay, bisexual, and other men who have sex with men (GBM) 26 years or younger in Canada. Methods: Self-identified GBM who reported having sex with another man within the past 6 months were enrolled using respondent-driven sampling (RDS) between February 2017 and August 2019 in Montreal, Toronto, and Vancouver, Canada. Men aged 16 to 30 years self-collected anal specimens for HPV-DNA testing. Prevalence was estimated using RDS-II weights. We compared the prevalence of quadrivalent (HPV-6/11/16/18) and 9-valent (HPV-6/11/16/18/31/33/45/52/58) vaccine types between GBM who self-reported HPV vaccination (≥1 dose) and those reporting no vaccination using a modified Poisson regression for binary outcomes. Results: Among 645 GBM who provided a valid anal specimen (median age, 26 years; 5.9% HIV positive), 40.3% reported receiving ≥1 dose of HPV vaccine, of whom 61.8% received 3 doses. One-quarter were infected with ≥1 quadrivalent type (crude, 25.7%; RDS weighted, 24.4%). After adjustment for potential confounders, vaccinated GBM had a 27% lower anal prevalence of quadrivalent types compared with unvaccinated GBM (adjusted prevalence ratio [aPR], 0.73; 95% confidence interval [CI], 0.54–1.00). Lower prevalence ratios were found among vaccinated participants who were vaccinated >2 years before enrollment (aPR, 0.47; 95% CI, 0.25–0.86) or received their first vaccine dose at age ≤23 years (aPR, 0.64; 95% CI, 0.42–0.99). Point estimates were similar for ≥2 or 3 doses and 9-valent types. Conclusions: Human papillomavirus vaccination was associated with a lower anal prevalence of vaccine-preventable HPV types among young, sexually active GBM. Findings will help inform shared decision making around HPV vaccination for GBM and their healthcare providers.Keywords
This publication has 20 references indexed in Scilit:
- The effect of HIV infection on anal and penile human papillomavirus incidence and clearanceAIDS, 2016
- Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: “STROBE-RDS” statementJournal of Clinical Epidemiology, 2015
- How to best measure the effectiveness of male human papillomavirus vaccine programmes?Clinical Microbiology and Infection, 2015
- Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysisThe Lancet Oncology, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Six-Month Incidence, Persistence, and Factors Associated With Persistence of Anal Human Papillomavirus in Men: The HPV in Men StudyThe Journal of Infectious Diseases, 2011
- Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping TestJournal of Clinical Microbiology, 2006
- Easy SAS Calculations for Risk or Prevalence Ratios and DifferencesAmerican Journal of Epidemiology, 2005
- Respondent-Driven Sampling: A New Approach to the Study of Hidden PopulationsSocial Problems, 1997
- Risk Factors for Oral Human Papillomavirus in Adults Infected and Not Infected With Human Immunodeficiency VirusSexually Transmitted Diseases, 1997